Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) Pty.

Vertex Pharmaceuticals (Australia) patent portfolio — 57 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
0
Drugs
37
Patents
57
Official website ↗ Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Vertex Pharmaceuticals (Australia) patents

57 pharmaceutical patents indexed for Vertex Pharmaceuticals (Australia). 0 expire within 24 months.

Vertex Pharmaceuticals (Australia) has 57 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

57 patents

Patent portfolio

Page 1 of 2

  1. US 12350262

    Methods of treatment for cystic fibrosis

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12214083

    Pharmaceutical composition and administrations thereof

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12186306

    Methods of treatment for cystic fibrosis

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12065432

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11951212

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11873300

    Crystalline forms of CFTR modulators

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11866450

    Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11834441

    Substituted tetrahydrofurans as modulators of sodium channels

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11752106

    Pharmaceutical composition and administrations thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11639347

    Modulators of ATP-binding cassette transporters

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11578062

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11564916

    Pharmaceutical composition and administrations thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11517564

    Methods of treatment for cystic fibrosis

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11453655

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11426407

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11179367

    Pharmaceutical compositions for treating cystic fibrosis

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11147770

    Pharmaceutical composition and administrations thereof

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11066417

    Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11052075

    Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10793547

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10758534

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10646481

    Pharmaceutical composition and administrations thereof

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10597384

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10272046

    Pharmaceutical composition and administrations thereof

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10239867

    Modulators of ATP-binding cassette transporters

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10206877

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10081621

    Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10076513

    Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10058546

    Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10022352

    Modulators of ATP-binding cassette transporters

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9974781

    Modulators of ATP-binding cassette transporters

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9931334

    Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9670163

    Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9216969

    Modulators of ATP-binding cassette transporters

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9192606

    Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9150552

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9012496

    Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8993600

    Modulators of ATP-binding cassette transporters

    Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8883206

    Pharmaceutical composition and administrations thereof

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8846718

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8754224

    Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8741933

    Modulators of ATP-binding cassette transporters

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8716338

    Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8664273

    Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin

    Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8653103

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8623905

    Modulators of ATP-binding cassette transporters

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8598181

    Modulators of ATP-binding cassette transporters

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8507534

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vertex Pharmaceuticals (Australia) have?

57 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vertex Pharmaceuticals (Australia) patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.